Ten months after pledging to expand a discount program for a drug that treats an HIV-related infection, Gilead Sciences (GILD) has registered its medicine in just six of 116 designated countries and, in some cases, failed to lower the price as promised, according to Doctors Without Borders. And the non-governmental organization is accusing the company of running a “public relations stunt.”
At issue is an injectable medication called AmBisome that is used to combat cryptococcal meningitis, which is the second biggest killer of people living with HIV, after tuberculosis, according to the group. And the World Health Organization estimates the infection is responsible for 15% of HIV-related deaths globally.
About the Author Reprints
